Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Key Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications.

The American journal of medicine·2024
Same author

Adherence in Hepatitis C Virus Treatment: What We Know.

Seminars in liver disease·2024
Same author

Clinical Consult in NASH: Are Your Patients at Risk? Based on a Medscape Education Online Activity.

The Journal of family practice·2023
Same author

Cholangiocarcinoma Surveillance Recommendations in Patients with Primary Sclerosing Cholangitis.

Clinics in liver disease·2023
Same author

Reply.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.

The American journal of gastroenterology·2023
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Selective Harvesting of Marginating-hepatic Leukocytes
06:53

Selective Harvesting of Marginating-hepatic Leukocytes

Published on: July 21, 2016

Granulomatous liver disease.

Steven L Flamm1

  • 1Division of Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. s-flamm@northwestern.edu

Clinics in Liver Disease
|May 1, 2012
PubMed
Summary
This summary is machine-generated.

Hepatic granulomata found in liver biopsies often signal underlying systemic diseases. Identifying the cause through medical history, exams, and tests is crucial for effective treatment of granulomatous hepatitis.

More Related Videos

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice
11:44

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice

Published on: March 24, 2015

Related Experiment Videos

Last Updated: May 22, 2026

Selective Harvesting of Marginating-hepatic Leukocytes
06:53

Selective Harvesting of Marginating-hepatic Leukocytes

Published on: July 21, 2016

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice
11:44

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice

Published on: March 24, 2015

Area of Science:

  • Hepatology
  • Pathology
  • Internal Medicine

Background:

  • Hepatic granulomata are commonly found during liver biopsies.
  • Their presence frequently indicates an associated systemic disease.
  • Clinical and biochemical presentations vary depending on the underlying condition.

Purpose of the Study:

  • To highlight the significance of detecting hepatic granulomata in liver biopsies.
  • To emphasize the need for a comprehensive workup to determine the etiology.
  • To outline the diagnostic approach and therapeutic principles for granulomatous hepatitis.

Main Methods:

  • Review of clinical presentations associated with hepatic granulomata.
  • Analysis of common biochemical abnormalities, including elevated serum alkaline phosphatase and γ-glutamyltransferase.
  • Discussion of diagnostic clues from medical history, physical examination, blood tests, and imaging.

Main Results:

  • Elevated serum alkaline phosphatase and γ-glutamyltransferase are the most frequent biochemical findings.
  • A systematic diagnostic approach is essential for identifying the cause of granulomatous hepatitis.
  • Treatment focuses on addressing the root systemic disease.

Conclusions:

  • The presence of hepatic granulomata necessitates further investigation to uncover the underlying systemic cause.
  • Early identification and management of the causative disease are key to treating granulomatous hepatitis.
  • Multidisciplinary diagnostic strategies are vital for patient care.